Blood-Brain Barrier Booming As A Source Of New Biotechnology Research Challenges

Industry observers predict increased opportunities as firms set their sights on novel techniques for drug delivery. 'HUGE EXPLOSION: Many potentially therapeutic brain molecules are a boon, asserts Richard Pops. Finding ways to sneak therapeutic drugs past the seemingly impenetrable blood-brain barrier -- a tightly bound wall of endothelial cells that protects the brain from pathogens and other substances -- is keeping a small cadre of biotech firms busy. Researchers at these companies, as

Written byKaren Young Kreeger
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share


Industry observers predict increased opportunities as firms set their sights on novel techniques for drug delivery.

'HUGE EXPLOSION: Many potentially therapeutic brain molecules are a boon, asserts Richard Pops.
Finding ways to sneak therapeutic drugs past the seemingly impenetrable blood-brain barrier -- a tightly bound wall of endothelial cells that protects the brain from pathogens and other substances -- is keeping a small cadre of biotech firms busy.

Researchers at these companies, as well as universities and the National Institutes of Health, are working on new drug-delivery techniques that can bypass the barrier and combat a host of diseases affecting the central nervous system (CNS). Observers see rich research and job opportunities in the not-too-distant future for neuroscientists and other investigators developing these delivery systems.

"With the aging of the U.S. population, neurology and diseases of the brain are going to become disproportionately important," predicts Nigel Webb, president and CEO ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies